<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825630</url>
  </required_header>
  <id_info>
    <org_study_id>HP-BID 608</org_study_id>
    <nct_id>NCT00825630</nct_id>
  </id_info>
  <brief_title>13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)</brief_title>
  <official_title>The Effect of High Dose Citric on PPI (Proton Pump Inhibitors)Induced False Negative H. Pylori UBT Rates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 200 patients with suspected H.pylori will be tested with a 13C-Urea Breath Test
      (UBT) to ascertain H.pylori positive. 100 H.Pylori positive patients will tested before and
      after prescribed with one of the four selected Proton Pump Inhibitors (PPIs); 25 patients in
      each arm. This will provide information on the influence of PPIs on the UBT (Urea Breath
      Test). The aim of the trial is to observe the effect of different PPIs on the breath test and
      choose the optimal protocol of when to stop PPI. The hypothesis is that there will be a
      minimal effect on the UBT while using selected PPIs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult subjects with suspected H pylori infection will be recruited and will undergo a 13C
      -Urea breath test (including citrica) with the BreathID test device. Those were found
      positive will undergo selected PPI treatment for 14 days and after 24 or 72 hours from the
      completion of the two weeks, will undergo a second breath test. Those found to be negative
      (false negative), will undergo additional breath tests.

        -  Those subjects that underwent any antibiotic, bismuth or PPI therapy 4 weeks prior to
           the trial, are to be excluded.

        -  Furthermore, pregnant or nursing women and subjects with an allergy or sensitivity to
           one of the tests substrates, will be excluded from the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urea Breath Test Result (DOB &gt; 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped.</measure>
    <time_frame>17 days</time_frame>
    <description>Negative value is defined as delta over baseline (DOB) less than 5. The subjects who were positive (DOB&gt;=5) for H.Pylori and after PPI for 10 days repeated a breath with a negative (DOB&lt;5) were considered false negatives. The breath test has been cleared by the FDA in a 510(k) and has &gt; 96% accuracy.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Lansoprazole (Lanton)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole (Losec)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pantoprazole (Controloc)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole(Nexium)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole (Lanton)</intervention_name>
    <description>Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection</description>
    <arm_group_label>Lansoprazole (Lanton)</arm_group_label>
    <other_name>Lanton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprezole (Losec)</intervention_name>
    <description>Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection</description>
    <arm_group_label>Omeprazole (Losec)</arm_group_label>
    <other_name>Losec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole(Controloc)</intervention_name>
    <description>Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection</description>
    <arm_group_label>Pantoprazole (Controloc)</arm_group_label>
    <other_name>Controloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole (Nexium)</intervention_name>
    <description>Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection</description>
    <arm_group_label>Esomeprazole(Nexium)</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with H.pylori infection.

        Exclusion Criteria:

          -  Pregnancy,

          -  Nursing,

          -  Antibiotic, bismuth or PPI treatment 2 weeks prior to trial,

          -  Known sensitivity to Urea or citrica.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haim Shirin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sharon Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Shirin H, Frenkel D, Shevah O, Levine A, Bruck R, Moss SF, Niv Y, Avni Y. Effect of proton pump inhibitors on the continuous real time (13)C-urea breath test. Am J Gastroenterol. 2003 Jan;98(1):46-50.</citation>
    <PMID>12526935</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <results_first_submitted>June 19, 2011</results_first_submitted>
  <results_first_submitted_qc>September 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 7, 2011</results_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HP</keyword>
  <keyword>UBT</keyword>
  <keyword>PPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Two out-patient clinics in hospitals will enroll subjects</recruitment_details>
      <pre_assignment_details>Size of arms varied due availability of PPI (proton pump inhibitors) and desire to gather more data in most common PPIs.Ethics committees approved additional recruitment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lansoprazole (Lanton)</title>
          <description>Patients with H.pylori infection will take Lanzoprazole orally in the morning (20 mg) for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Omeprazole( Losec)</title>
          <description>Patients with H.pylori infection will take Omeprazole orally in the morning (30mg) for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Pantoprazole (Controloc)</title>
          <description>Patients with H.pylori infection will take Pantoprazole orally in the morning (20mg) for 14 days</description>
        </group>
        <group group_id="P4">
          <title>Esomeprazole (Nexium)</title>
          <description>Patients with H.pylori infection will take Esomeprazole orally in the morning (40mg) for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lansoprazole (Lanton)</title>
          <description>Patients with H.pylori infection will take Lanzoprazole orally in the morning (20 mg) for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Omeprazole( Losec)</title>
          <description>Patients with H.pylori infection will take Omeprazole orally in the morning (30mg) for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Pantoprazole (Controloc)</title>
          <description>Patients with H.pylori infection will take Pantoprazole orally in the morning (20mg) for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Esomeprazole (Nexium)</title>
          <description>Patients with H.pylori infection will take Esomeprazole orally in the morning (40mg) for 14 days</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.86" spread="14.67"/>
                    <measurement group_id="B2" value="52.48" spread="13.35"/>
                    <measurement group_id="B3" value="51.84" spread="12.78"/>
                    <measurement group_id="B4" value="55.38" spread="14.84"/>
                    <measurement group_id="B5" value="52.46" spread="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>H. Pyori Positive</title>
          <description>Basline particpants include all those with suspected H.pylori infection that are tested with the FDA cleared BreathID 13C urea breath test and are found to be positive, that is DOB (delta over baseline) &gt;=5</description>
          <units>particpants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urea Breath Test Result (DOB &gt; 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped.</title>
        <description>Negative value is defined as delta over baseline (DOB) less than 5. The subjects who were positive (DOB&gt;=5) for H.Pylori and after PPI for 10 days repeated a breath with a negative (DOB&lt;5) were considered false negatives. The breath test has been cleared by the FDA in a 510(k) and has &gt; 96% accuracy.</description>
        <time_frame>17 days</time_frame>
        <population>Analysis was done on an ITT basis and approximately 25 subjects per group were anticipated in order to obtain a general evaluation of which PPI is will cause the least amount of false negatives.The actual amount of subjects in each group will depend upon the availability of the different PPIs through the course of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole (Lanton)</title>
            <description>Patients with H.pylori infection will take Lanzoprazole orally in the morning (20 mg) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Omeprazole( Losec)</title>
            <description>Patients with H.pylori infection will take Omeprazole orally in the morning (30mg) for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Pantoprazole (Controloc)</title>
            <description>Patients with H.pylori infection will take Pantoprazole orally in the morning (20mg) for 14 days</description>
          </group>
          <group group_id="O4">
            <title>Esomeprazole (Nexium)</title>
            <description>Patients with H.pylori infection will take Esomeprazole orally in the morning (40mg) for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Urea Breath Test Result (DOB &gt; 5 is Positive)After Different Time Periods From When PPI (Proton Pump Inhibitor) Was Stopped.</title>
          <description>Negative value is defined as delta over baseline (DOB) less than 5. The subjects who were positive (DOB&gt;=5) for H.Pylori and after PPI for 10 days repeated a breath with a negative (DOB&lt;5) were considered false negatives. The breath test has been cleared by the FDA in a 510(k) and has &gt; 96% accuracy.</description>
          <population>Analysis was done on an ITT basis and approximately 25 subjects per group were anticipated in order to obtain a general evaluation of which PPI is will cause the least amount of false negatives.The actual amount of subjects in each group will depend upon the availability of the different PPIs through the course of the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>False negatives (DOB&lt;5) after 3 days of no PPI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>False negatives (DOB&lt;5) after 1 day of no PPI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lansoprazole (Lanton)</title>
          <description>Patients with H.pylori infection will take Lanzoprazole orally in the morning (20 mg) for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Omeprazole( Losec)</title>
          <description>Patients with H.pylori infection will take Omeprazole orally in the morning (30mg) for 14 days</description>
        </group>
        <group group_id="E3">
          <title>Pantoprazole (Controloc)</title>
          <description>Patients with H.pylori infection will take Pantoprazole orally in the morning (20mg) for 14 days</description>
        </group>
        <group group_id="E4">
          <title>Esomeprazole (Nexium)</title>
          <description>Patients with H.pylori infection will take Esomeprazole orally in the morning (40mg) for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It was hard to get people to agree to return for multiple tests within a few days, so the enrollment was difficult</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Haim Shirin</name_or_title>
      <organization>Sharon Hospital</organization>
      <phone>0097239372231</phone>
      <email>haims3@clalit.org.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

